Xin Lang Cai Jing·2026-02-10 08:39Core Viewpoint - Fosun Pharma announced that its subsidiary Shanghai Chaohui Pharmaceutical's registration application for the drug Benzocaine Hydrochloride Gel has been accepted by the National Medical Products Administration. This drug is independently developed by the group for transdermal local anesthesia [1] Group 1: Drug Development and Financials - The drug is expected to have a cumulative R&D investment of approximately 7.19 million yuan by December 2025 [1] - The projected sales revenue for the drug in China is approximately 443 million yuan in 2024 [1] - The commercialization of the drug requires multiple approvals, and the current acceptance does not impact the company's performance at this stage, indicating uncertainty in sales [1]